Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc." New Corporate Name and Updated Stock Ticker Symbol to Showcase Company's Post-Merger Transformation...
Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast Audio archive for the event may be accessed from the "Investors" section of the Cytocom...
Cytocom, Inc. Reports Second Quarter 2021 Financial Results -All-stock merger transaction between legacy Cleveland BioLabs and legacy Cytocom recently completed; Cytocom, Inc. common stock...
Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement Cytocom to fund research in cancer, autoimmune and inflammatory conditions, and infectious...
Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference Mike K. Handley, President and CEO, will participate as featured panelist PR...
Cytocom, Inc. to Report Second Quarter 2021 Financial Results Executive Management to Host Conference Call on Monday, August 16th at 8:30 a.m. ET PR Newswire FORT COLLINS, Colo., Aug. 10, 2021...
Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19 Patient enrollment in Phase 3 pediatric Crohn's disease trial expected to...
Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs PR Newswire FORT COLLINS, Colo., Aug. 5, 2021 FORT COLLINS, Colo., Aug. 5, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ:...
Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing Financing Led by GEM Global Yield LLC SCS, and Joined by Avenue Capital, and Adit Ventures PR Newswire FORT...
Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger Special Investor Call will be held Wednesday, July 7, at 8:30 a.m. ET PR...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.